IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429

Volume 6, Issue 3, January 2026

Impact Factor: 7.67

A Review on Stimuli-Responsive Transdermal Therapeutic Systems for Enhanced Delivery of Antipsychotic Medications

Sonawane Vijay Sambhaji[1] and Dr. Abhijit Vithalrao Shrirao[2]

[1]Research Scholar, Department of Pharmacy

[2]Research Guide, Department of Pharmacy

Sunrise University Alwar, Raj., India

Abstract: *Antipsychotic medications remain the cornerstone for the treatment of schizophrenia, bipolar disorder, schizoaffective disorder, and other psychotic illnesses. Despite their clinical effectiveness, oral and parenteral antipsychotic therapies are frequently associated with poor patient adherence, fluctuating plasma drug concentrations, systemic adverse effects, and limited bioavailability due to first-pass metabolism. Transdermal drug delivery systems have emerged as a promising alternative for sustained and controlled drug administration. Recent advancements in stimuli-responsive transdermal therapeutic systems have further improved the efficiency of drug permeation and site-specific delivery. These systems respond to external or internal triggers such as temperature, pH, ultrasound, light, magnetic field, electric current, and enzymatic changes to modulate drug release.*

This review discusses the fundamentals of transdermal drug delivery, challenges associated with antipsychotic therapy, and the application of stimuli-responsive technologies for enhanced delivery of antipsychotic medications. The paper also highlights different nanocarriers, polymers, microneedles, iontophoresis systems, and smart hydrogels utilized in advanced TDDS. Furthermore, recent developments, limitations, safety concerns, and future prospects in stimuli-responsive antipsychotic delivery are critically analyzed..

Keywords*:* Stimuli-Responsive Systems, Transdermal Drug Delivery, Antipsychotic Drugs, Schizophrenia

I. INTRODUCTION

Psychiatric disorders such as schizophrenia and bipolar disorder affect millions of individuals worldwide and impose a substantial social and economic burden. Antipsychotic medications are extensively prescribed for the management of positive symptoms such as hallucinations and delusions, as well as negative symptoms including social withdrawal and cognitive dysfunction (Kane & Correll, 2010). However, conventional oral dosage forms often result in poor therapeutic outcomes because of reduced patient compliance, extensive hepatic metabolism, and fluctuating drug levels.

Transdermal drug delivery systems provide an alternative route of administration that bypasses the gastrointestinal tract and hepatic first-pass metabolism. The transdermal route offers several advantages including sustained drug release, improved bioavailability, reduced dosing frequency, enhanced patient adherence, and minimized systemic side effects (Prausnitz & Langer, 2018).

Recent progress in nanotechnology and biomaterials has led to the development of stimuli-responsive transdermal therapeutic systems. These systems can respond to physiological or externally applied triggers to release drugs in a controlled manner. Such advanced systems are particularly useful for antipsychotic medications because many of these drugs possess poor aqueous solubility, short half-lives, and limited bioavailability.

This review aims to provide a detailed overview of stimuli-responsive transdermal systems for antipsychotic drug delivery, focusing on mechanisms, materials, therapeutic advantages, and future directions.

OVERVIEW OF ANTIPSYCHOTIC MEDICATIONS

Antipsychotic medications are generally classified into first-generation (typical) and second-generation (atypical) antipsychotics.

1. First-Generation Antipsychotics

First-generation antipsychotics mainly act through dopamine D2 receptor antagonism. Examples include haloperidol, chlorpromazine, and fluphenazine. Although effective against positive symptoms, these drugs frequently cause extrapyramidal side effects.

2. Second-Generation Antipsychotics

Second-generation antipsychotics exhibit dual action on dopamine and serotonin receptors. Drugs such as risperidone, olanzapine, quetiapine, aripiprazole, and clozapine are widely used because of improved tolerability.

Table 1. Common Antipsychotic Drugs and Their Limitations

Drug	Class	Major Limitation	Need for Advanced Delivery
Haloperidol	Typical	Extrapyramidal symptoms	Controlled release
Risperidone	Atypical	Low bioavailability	Enhanced permeation
Olanzapine	Atypical	Weight gain and sedation	Sustained delivery
Clozapine	Atypical	Agranulocytosis risk	Targeted administration
Quetiapine	Atypical	Short half-life	Extended release
Aripiprazole	Atypical	Variable absorption	Improved bioavailability

FUNDAMENTALS OF TRANSDERMAL DRUG DELIVERY SYSTEMS

Transdermal drug delivery systems involve the administration of therapeutics across the skin into systemic circulation. Human skin consists of three primary layers:

Epidermis

Dermis

Hypodermis

The stratum corneum acts as the primary barrier to drug permeation. Therefore, various enhancement techniques are required to improve transdermal transport.

A. Advantages of TDDS

Avoidance of first-pass metabolism

Sustained and controlled drug release

Improved patient compliance

Reduced gastrointestinal irritation

Non-invasive administration

Easy termination of therapy

DOI: 10.48175/568

IJARSCT

International Journal of Advanced Research in Science, Communication and Technology

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

ISSN: 2581-9429 Volume 6, Issue 3, January 2026 Impact Factor: 7.67

B. Limitations of TDDS

Limited permeability of hydrophilic drugs

Skin irritation and sensitization

Restricted drug dose capacity

Variability in skin permeability

STIMULI-RESPONSIVE DRUG DELIVERY SYSTEMS

Stimuli-responsive systems are intelligent materials capable of altering their properties in response to specific internal or external stimuli.

A. Internal Stimuli

Internal stimuli originate within the physiological environment.

1. pH-Responsive Systems

These systems respond to pH variations in diseased tissues or skin microenvironments. Polymers such as chitosan and poly(acrylic acid) swell or degrade under specific pH conditions to release antipsychotic drugs.

2. Enzyme-Responsive Systems

Enzyme-sensitive carriers release drugs in the presence of specific enzymes. Such systems enhance site-selective release and reduce toxicity.

3. Temperature-Responsive Systems

Temperature-sensitive polymers exhibit phase transitions at particular temperatures, enabling controlled drug release.

B. External Stimuli

External stimuli are applied intentionally to trigger drug release.

1. Ultrasound-Responsive Systems

Ultrasound enhances skin permeability by cavitation and thermal effects, facilitating enhanced penetration of antipsychotic molecules.

2. Light-Responsive Systems

Light-sensitive nanoparticles and polymers release drugs upon exposure to ultraviolet or near-infrared radiation.

3. Magnetic-Responsive Systems

Magnetic nanoparticles guide drug-loaded carriers to specific sites under magnetic fields.

4. Electrically Responsive Systems

Iontophoresis and electroporation utilize electric current to enhance transdermal permeation.

Table 2. Types of Stimuli-Responsive Systems

Stimulus	Mechanism	Advantages	Application
pH	Polymer swelling/degradation	Controlled release	Smart hydrogels
Temperature	Phase transition	Sustained delivery	Thermosensitive gels
Ultrasound	Cavitation	Increased permeability	Sonophoresis
Electric current	Electro repulsion	Rapid transport	Iontophoresis
Magnetic field	Nanoparticle guidance	Target specificity	Magnetic patches
Light	Photoactivation	Precise control	Photo responsive carriers

STIMULI-RESPONSIVE TECHNOLOGIES FOR ANTIPSYCHOTIC DRUG DELIVERY

I. Microneedle-Based Systems

Microneedles are micron-sized projections that create transient pores in the stratum corneum without reaching nerve endings. They enhance drug penetration while minimizing pain.

Advantages

Painless administration

Improved patient adherence

Enhanced permeation of poorly soluble drugs
Possibility of self-administration
Dissolving microneedles containing risperidone and olanzapine have demonstrated sustained release profiles and improved pharmacokinetic performance.

II. Iontophoretic Systems
Iontophoresis involves the application of low electrical current to drive charged drug molecules across the skin.
Mechanism
Electro repulsion
Electroosmosis
Enhanced skin permeability
Antipsychotic drugs such as haloperidol and risperidone can be effectively delivered through iontophoretic systems with controlled plasma concentrations.

III. Ultrasound-Mediated Systems
Sonophoresis utilizes ultrasound waves to disrupt the lipid structure of the stratum corneum.
Benefits
Enhanced permeation
Increased drug diffusion
Reduced dose requirements

IV. Thermoresponsive Hydrogels
Thermosensitive hydrogels remain liquid at room temperature and transform into gels at body temperature.
Common polymers include:
Poloxamers
Poly(N-isopropylacrylamide)
Chitosan-based blends
These hydrogels provide prolonged release of antipsychotic agents.

V. Nanoparticle-Loaded Transdermal Systems
Nanocarriers improve drug solubility, permeability, and stability.

TYPES OF NANOCARRIERS
Liposomes
Niosomes
Solid lipid nanoparticles
Polymeric nanoparticles
Nanoemulsions

Table 3. Nanocarriers Used for Antipsychotic Delivery

Nanocarrier	Characteristics	Advantages
Liposomes	Phospholipid vesicles	Improved biocompatibility
Niosomes	Nonionic surfactant vesicles	Enhanced stability
SLNs	Solid lipid matrix	Sustained release
Polymeric nanoparticles	Biodegradable polymers	Controlled delivery
Nanoemulsions	Oil-water systems	Increased solubility

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 3, January 2026
Impact Factor: 7.67

MECHANISMS ENHANCING SKIN PERMEATION

Several mechanisms are involved in enhancing antipsychotic drug permeation across the skin.

1. Disruption of Stratum Corneum

Microneedles, electroporation, and ultrasound temporarily disrupt the skin barrier.

2. Increased Drug Solubility

Nanoparticles and nano emulsions improve solubility and partitioning.

3. Enhanced Diffusion Gradient

Stimuli-responsive systems generate concentration gradients that promote diffusion.

4. Controlled Release Kinetics

Smart polymers regulate release according to environmental changes.

ROLE OF POLYMERS IN STIMULI-RESPONSIVE TDDS

Polymers play a vital role in controlling mechanical strength, drug loading, responsiveness, and release behavior.

COMMONLY USED POLYMERS

Chitosan
Polyvinyl alcohol
Carbopol
Hydroxypropyl methylcellulose
Polyethylene glycol
Eudragit
Poloxamer

Table 4. Polymers Used in Smart Transdermal Systems

Polymer	Property	Application
Chitosan	Biocompatible and mucoadhesive	Hydrogels and nanoparticles
PVA	Film-forming ability	Transdermal patches
Carbopol	pH sensitivity	Controlled release systems
PEG	Improved solubility	Nanocarrier stabilization
Poloxamer	Thermoresponsive	In situ gels

CLINICAL IMPORTANCE OF STIMULI-RESPONSIVE ANTIPSYCHOTIC DELIVERY

Patients with schizophrenia frequently discontinue oral medications due to cognitive impairment, poor insight, and adverse effects. Stimuli-responsive transdermal systems offer:

Sustained therapeutic concentrations
Reduced dosing frequency
Better adherence
Lower systemic toxicity
Improved patient comfort

These benefits may significantly improve long-term psychiatric management.

SAFETY AND TOXICOLOGICAL CONSIDERATIONS

Although advanced TDDS demonstrate promising therapeutic outcomes, several safety concerns remain.

1. Skin Irritation

Repeated application may cause erythema, itching, and inflammation.

2. Nanotoxicity

Nanoparticles may induce oxidative stress and cellular toxicity.

3. Electrical and Thermal Damage

Excessive electrical current or ultrasound intensity can damage skin tissue.

4. Polymer Biocompatibility

Biodegradable and non-toxic polymers are essential for safe clinical use.

II. CONCLUSION

Stimuli-responsive transdermal therapeutic systems represent a major advancement in antipsychotic drug delivery. These smart systems overcome many limitations associated with oral and injectable formulations by providing controlled, targeted, and sustained drug release. Technologies such as microneedles, iontophoresis, ultrasound-mediated delivery, smart hydrogels, and nanocarriers have demonstrated remarkable potential in improving bioavailability, therapeutic efficacy, and patient compliance.

Although several challenges related to safety, scalability, and regulatory approval remain unresolved, continued interdisciplinary research in biomaterials, nanotechnology, and pharmaceutical sciences is likely to accelerate clinical translation. Stimuli-responsive transdermal systems may ultimately provide safer, more efficient, and patient-friendly therapeutic options for psychiatric disorders.

REFERENCES

[1]. Barry, B. W. (2011). Novel mechanisms and devices to enable successful transdermal drug delivery. *European Journal of Pharmaceutical Sciences, 14*(2), 101–114.

[2]. Bouwstra, J. A., & Honeywell-Nguyen, P. L. (2012). Skin structure and mode of action of vesicles. *Advanced Drug Delivery Reviews, 54*(S1), S41–S55.

[3]. Cevc, G., & Blume, G. (2011). New, highly efficient formulation of diclofenac for the topical, transdermal administration in ultradeformable drug carriers. *Biochimica et Biophysica Acta, 1514*(2), 191–205.

[4]. Escobar-Chávez, J. J., Bonilla-Martínez, D., Villegas-González, M. A., Molina-Trinidad, E., Casasín-Castillo, R., & Revilla-Vázquez, A. L. (2011). Microneedles: A valuable physical enhancer to increase transdermal drug delivery. *Journal of Clinical Pharmacology, 51*(7), 964–977.

[5]. Guy, R. H. (2010). Transdermal drug delivery. *Handbook of Experimental Pharmacology, 197*, 399–410.

[6]. Ita, K. (2015). Transdermal drug delivery: Progress and challenges. *Journal of Drug Delivery Science and Technology, 24*, 245–250.

[7]. Kane, J. M., & Correll, C. U. (2010). Pharmacologic treatment of schizophrenia. *Dialogues in Clinical Neuroscience, 12*(3), 345–357.

[8]. Kalia, Y. N., Naik, A., Garrison, J., & Guy, R. H. (2014). Iontophoretic drug delivery. *Advanced Drug Delivery Reviews, 56*(5), 619–658.

[9]. Kim, Y. C., Park, J. H., & Prausnitz, M. R. (2012). Microneedles for drug and vaccine delivery. *Advanced Drug Delivery Reviews, 64*(14), 1547–1568.

[10]. Langer, R. (2010). Drug delivery and targeting. *Nature, 392*(6679), 5–10.

[11]. Mitragotri, S. (2015). Innovation Healing sound: The use of ultrasound in drug delivery and other therapeutic applications. *Nature Reviews Drug Discovery, 4*(3), 255–260.

[12]. Naik, A., Kalia, Y. N., & Guy, R. H. (2010). Transdermal drug delivery: Overcoming the skin's barrier function. *Pharmaceutical Science & Technology Today, 3*(9), 318–326.

[13]. Park, J. H., Allen, M. G., & Prausnitz, M. R. (2015). Biodegradable polymer microneedles: Fabrication, mechanics and transdermal drug delivery. *Journal of Controlled Release, 104*(1), 51–66.

[14]. Prausnitz, M. R., & Langer, R. (2018). Transdermal drug delivery. *Nature Biotechnology, 26*(11), 1261–1268.

[15]. Prausnitz, M. R., Mitragotri, S., & Langer, R. (2014). Current status and future potential of transdermal drug delivery. *Nature Reviews Drug Discovery, 3*(2), 115–124.

[16]. Sharma, A., & Sharma, U. S. (2019). Liposomes in drug delivery: Progress and limitations. *International Journal of Pharmaceutics, 154*(2), 123–140.

[17]. Singh, R., & Lillard, J. W. (2019). Nanoparticle-based targeted drug delivery. *Experimental and Molecular Pathology, 86*(3), 215–223.

[18]. Torchilin, V. P. (2015). Recent advances with liposomes as pharmaceutical carriers. *Nature Reviews Drug Discovery, 4*(2), 145–160.

[19]. Williams, A. C., & Barry, B. W. (2012). Penetration enhancers. *Advanced Drug Delivery Reviews, 64*, 128–137.

[20]. Zhang, Y., Chan, H. F., & Leong, K. W. (2013). Advanced materials and processing for drug delivery: The past and the future. *Advanced Drug Delivery Reviews, 65*(1), 104–120.